Patent application number | Description | Published |
20080260641 | Human Monoclonal Antibodies Against Cd20 - Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 10-23-2008 |
20090076249 | Antibodies against CD38 for treatment of multiple myeloma - Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 03-19-2009 |
20090081219 | Human monoclonal antibodies against CD25 - Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 03-26-2009 |
20090117584 | Non-Human mammalian Arthritis Model Featuring Human Antibodies Against Citrul-Linated Proteins - Use of a non-human mammalian disease model, wherein the non-human mammal has been implanted with human synovial tissue or other human inflamed tissue containing anti-CCP (cyclic citrullinated peptide) antibody producing cells for (i) analyzing cellular processes in a disease associated with anti-CCP antibodies in such human synovial tissue or other human inflamed tissue, (ii) studying the role of anti-CCP antibodies in the induction and progression of a disease associated with anti-CCP antibodies, (iii) testing the efficacy of a therapeutic agent for the prevention or treatment of a disease associated with anti-CCP antibodies, and (iv) identifying a therapeutic agent useful for the prevention or treatment of a disease associated with anti-CCP antibodies. In one embodiment the non-human mammalian disease model is a mouse, such as a SCID mouse, and the disease associated with anti-CCP antibodies is arthritis, such as RA (rheumatoid arthritis). | 05-07-2009 |
20090148449 | Antibodies against cd38 for treatment of multiple myeloma - Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 06-11-2009 |
20090155204 | Methods for treating disorders involving monocytes - Methods for treating disorders involving monocytic activity by administering IL-15 antagonists that induce apoptosis of monocytes are disclosed. | 06-18-2009 |
20090275126 | ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND USES THEREOF - Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy. | 11-05-2009 |
20090311779 | ANTI-P-SELECTIN ANTIBODIES - This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD). | 12-17-2009 |
20090317382 | USE OF EFFECTOR-FUNCTION-DEFICIENT ANTIBODIES FOR TREATMENT OF AUTO-IMMUNE DISEASES - The invention relates to the treatment of autoimmune diseases and disorders, in particular myasthenia gravis, by administration of effector-function-deficient antibodies, wherein said effector-function-deficient antibodies are capable of competing with one or more of the auto-antibodies involved in mediating the antibody-mediated auto-immune disease or disorder for binding to a target auto-antigen. | 12-24-2009 |
20100015134 | Therapy With CD4 Binding Peptides and Radiation - The present invention relates to a peptide, such as an antibody, capable of binding to CD4 and use thereof for the mediation of radiation treatment of a clinical condition. The radiation treatment may for instance by treatment with PUVA. | 01-21-2010 |
20100015644 | Potency assays for antibody drug substance binding to an fc receptor - The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor. | 01-21-2010 |
20100041874 | HIGH THROUGHPUT METHODS FOR CHARACTERIZATION OF ANTIBODIES - The invention relates to methods for the characterization of monoclonal antibodies, in particular high throughput methods for the characterization of antibodies with respect to internalization and complement activation. | 02-18-2010 |
20100092489 | COMBINATION TREATMENT OF CD38-EXPRESSING TUMORS - The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent. | 04-15-2010 |
20100105874 | BISPECIFIC ANTIBODIES AND METHODS FOR PRODUCTION THEREOF - The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention. | 04-29-2010 |
20100166740 | Anti-OX40L antibodies - This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases. | 07-01-2010 |
20100255012 | RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING - Glycosylated monovalent antibodies binding to selected antigens with a low or lacking fucose content, which are capable of inducing antibody dependent cellular cytotoxicity (ADCC) on cells expressing the selected antigens in the presence of effector cells, methods for producing the monovalent antibodies, pharmaceutical compositions comprising such monovalent antibodies and use thereof for different diagnostic and therapeutic applications. | 10-07-2010 |
20100267934 | STABLE IGG4 ANTIBODIES - The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370). | 10-21-2010 |
20100291023 | METHOD FOR EXTENDING THE HALF-LIFE OF EXOGENOUS OR ENDOGENOUS SOLUBLE MOLECULES - The present invention relates to methods for extending the in vivo half-life of an exogenous soluble therapeutic molecule administered to a subject, by administering to said subject the exogenous soluble molecule and a monovalent antibody that binds to the exogenous soluble molecule, as well as method for treating a disease or disorder associated with an insufficient level of an endogenous soluble molecule in a subject, by administering to said subject a monovalent antibody that binds to the endogenous soluble molecule. | 11-18-2010 |
20100303823 | HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) - Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 12-02-2010 |
20100306867 | TRANSGENIC ANIMALS PRODUCING MONOVALENT HUMAN ANTIBODIES AND ANTIBODIES OBTAINABLE FROM THESE ANIMALS - The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods. | 12-02-2010 |
20100325744 | NON-GLYCOSYLATED RECOMBINANT MONOVALENT ANTIBODIES - The present invention provides non-glycosylated monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies. | 12-23-2010 |
20110038869 | MONOCLONAL ANTIBODIES AGAINST CD32B - Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies. | 02-17-2011 |
20110045007 | FUSION OR LINKED PROTEINS WITH EXTENDED HALF LIFE - The present invention provides fusion proteins comprising a first molecule, and a second molecule which is a monovalent immunoglobulin or a fragment of a monovalent immunoglobulin with a long half-life when administered in vivo, methods of making such fusion proteins, pharmaceutical compositions comprising such fusion proteins, and uses thereof. | 02-24-2011 |
20110070239 | ANTI-OX40L ANTIBODIES - This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C | 03-24-2011 |
20110086026 | ANTIBODIES AGAINST IL-13 RECEPTOR ALPHA 1 AND USES THEREOF - An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases. | 04-14-2011 |
20110091473 | NOVEL ANTIBODY THERAPIES - Antibody capable of mediating effector function which specifically binds to a multiple membrane spanning antigen or to an antigen which forms dimers or multimers (i) for use in combination with a cholesterol-increasing agent in the treatment of a disease or disorder associated with said antigen, wherein antibody-induced effector function has a beneficial effect on said disease or disorder or (ii) for use in the treatment of such disease or disorder, wherein the antibody is to be administered to a subject undergoing therapy with a cholesterol-lowering agent, such as a statin, and wherein the subject is withdrawn from treatment with the cholesterol-lowering agent prior to the administration of the antibody. Furthermore, a kit of parts comprising such antibody as well as a cholesterol-increasing agent. | 04-21-2011 |
20110293607 | Antibody Variants Having Modifications In The Constant Region - The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed. | 12-01-2011 |
20110300156 | HUMAN ANTIBODIES AGAINST TISSUE FACTOR - Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies. | 12-08-2011 |
20120020952 | METHODS FOR PRODUCING MIXTURES OF ANTIBODIES - The invention relates to a method for producing a mixture comprising two or more different antibodies in a single recombinant host cell. In one embodiment, a mixture of different monovalent antibodies is produced. In another embodiment, a mixture of monovalent and bivalent antibodies is produced. The invention also relates to mixtures of antibodies obtainable by the method of the invention and to light chain sequences that are particularly useful in the method of the invention. | 01-26-2012 |
20120164143 | HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) - Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 06-28-2012 |
20130004480 | CD20 Binding Molecules for the Treatment of Copd - Use of CD20 binding molecules, such as anti-CD20 antibodies, for the treatment of chronic obstructive pulmonary disease (COPD). | 01-03-2013 |
20130039913 | HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF - Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins. | 02-14-2013 |
20130101608 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR - Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates. | 04-25-2013 |
20130171148 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE - Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 07-04-2013 |
20130189271 | MONOCLONAL ANTIBODIES AGAINST HER2 - Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 07-25-2013 |
20130209355 | ANTIBODIES AGAINST HUMAN CD38 - Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies. | 08-15-2013 |
20130216548 | MONOCLONAL ANTIBODIES AGAINST C-MET - Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 08-22-2013 |
20130345406 | STABLE IGG4 ANTIBODIES - The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370). | 12-26-2013 |
20140030273 | HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74 - Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed. | 01-30-2014 |
20140170148 | BISPECIFIC ANTIBODIES AGAINST HER2 - Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed. | 06-19-2014 |
20140170149 | BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3 - Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed. | 06-19-2014 |
20140170156 | HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) - Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 06-19-2014 |
20140242075 | ANTIBODY VARIANTS AND USES THEREOF - Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response. | 08-28-2014 |
20140271623 | MODULATION OF COMPLEMENT-DEPENDENT CYTOTOXICITY THROUGH MODIFICATIONS OF THE C-TERMINUS OF ANTIBODY HEAVY CHAINS - Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described. | 09-18-2014 |
20140303356 | PRODUCTION OF HETERODIMERIC PROTEINS - The present invention relates to an in vitro method for production of heterodimeric proteins. | 10-09-2014 |
20140348833 | NOVEL METHODS AND ANTIBODIES FOR TREATING CANCER - The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein
| 11-27-2014 |